CCM
SANA icon

CAAS Capital Management’s Sana Biotechnology SANA Stock Holding History

CAAS Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60,000
Closed -$2.01M – 1246
2021
Q1 		$2.01M Buy
+60,000
New +$1.95M 0.02% 594

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAAS Capital Management's SANA Position: Q2 2021 in Review

CAAS Capital Management sold out of Sana Biotechnology (SANA) in Q2 2021, closing a stake of 60,000 shares — an estimated $2.01M sold.

CAAS Capital Management first reported a position in SANA in Q1 2021 and held it in 1 quarter. The position peaked at $2.01M in Q1 2021. 80 funds tracked by Wall St. Rank hold SANA as of Q2 2021.

  • CAAS Capital Management reported no remaining Sana Biotechnology position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 60,000 Sana Biotechnology shares in Q2 2021, an estimated $2.01M.
  • CAAS Capital Management first reported a position in Sana Biotechnology in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Sana Biotechnology position peaked at $2.01M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.